Scandinavian Medical Solutions har her til morgen aflagt halvårsrapporten for 2024/25, der dækker perioden 1. oktober 2024 til 31. marts 2025. Trods en omsætningsvækst på 20% faldt selskabets EBITDA til DKK 0,6 mio.

Read the latest Hafnia One-pager update following the Q1 2025 results. The One-pager includes a brief company profile, a market update on product tankers, the latest financial performance, and valuation perspectives relative to peers. It also outlines several key investment risks and reasons to consider Hafnia as an investment case.

Dagens aktienyheder med Scandinavian Medical Solutions, Ascelia Pharma, Wirtek og Aktier med Friis

The company today published its financial results for the first quarter of 2025. The most significant event during the quarter was the outcome of the planned meeting with the U.S. Food and Drug Administration (FDA).

Orthex's Q1 figures were disappointing, as credit risk management, fewer campaigns than in the comparison period, and the impact of Finnish strikes pushed revenue into decline and earnings well below the comparison period.

Björn Borg delivered a solid Q1 report, broadly in line with our expectations. As a result, we are maintaining our estimates largely unchanged. However, despite the good Q1 performance, the share price has risen nearly 20% since our last update. At current valuation levels, we view the risk/reward profile as less attractive. Consequently, we turn to a Reduce recommendation (prev. Accumulate) but maintain our target price of SEK 55 per share.

Overall, Metacon’s Q1 report was better than expected, and the company has continued to grow its order intake since the end of the quarter, supporting our estimates for sustained growth. That said, we acknowledge the significant risks and uncertainties regarding the company’s ability to consistently secure large orders and maintain sufficient working capital to fulfill them. While liquidity is expected to remain tight until June/July 2025, when we anticipate the release of a significant portion of restricted cash tied to previously announced orders, we believe Metacon is well-positioned to secure short-term project financing on reasonable terms, if needed. With improved near-term revenue visibility, where our 2025 revenue estimates are largely “secured” by the existing order book, we believe the current valuation offers an attractive risk/reward profile. As a result, we reiterate our Accumulate recommendation with an increased target price of SEK 0.23 (was SEK 0.16), mainly due to an upward revision of our estimates.

NIBE’s Q1 result was operationally largely in line with our expectations, and we made only minor upside revisions to our short-term earnings estimates. The company's outlook and market indicators continue to show signs of a recovery in the destocking situation. However, a meaningful recovery is likely to take time to materialize due to a slow recovery in consumer confidence and purchasing power, as well as in the new-build market. In our view, short-term drivers remain weak, and the stock is already sufficiently priced in for high earnings growth (2025e P/E: 31x). As a result, we reiterate our Reduce recommendation and our target price to SEK 40.0 per share.

Fredag i sidste uge havde vi fornøjelsen at afholde event med Gabriel, hvor CEO Anders Hedegaard Petersen præsenterede regnskabet for 2. kvartal 2024/25, og kom omkring den seneste udvikling i både de fortsættende og ophørende aktiviteter. Fik du ikke set med kan du se optagelsen her.

Fik du ikke set med i sidste uge, hvor TORM's CFO Kim Balle præsenterede regnskabet for 1. kvartal 2025, har du muligheden for at se optagelsen her.

Se eller gense vores præsentation fra sidste uge med Skjern Bank, hvor bankdirektør Per Munck gennemgår regnskabet for 1. kvartal 2025.

Today, ExpreS2ion Biotechnologies’ CEO, Bent Frandsen, presented the results for the first quarter of 2025, provided further insights into the recent pipeline developments, and shared the latest updates on partnerships aimed at commercializing the company’s technology platform

Se med når CEO i DFDS – Torben Carlsen – præsenterer regnskabet for 1. kvartal 2025 og dermed også løfter sløret for hvordan året er startet for DFDS. Præsentationen finder sted som et online event - torsdag d. 15. maj kl. 15.00 - hvor der er mulighed for at høre ledelsens udlægning af året, og blive klogere på hvad vi kan forvente os ind i resten af 2025.

Viva Wine, the main competitor of Anora's Wine segment, announced its Q1 result on Thursday. Although the timing of Easter weighed on Viva's performance as well, the company continued to gain market share in the Nordic countries.

Yesterday, Wirtek reported its Q1 2025 results. Despite challenging market conditions and a decline in revenue and EBITDA, the company maintained its full-year 2025 guidance. We have updated our investment case one-pager following the recent results and news.

RTX ventes at offentliggøre sit kvartalsregnskab for Q2 2024/25 – d. 13. maj 2025. Ugen efter - torsdag d. 15. maj kl. 11.30 – har vi fornøjelsen at indbyde til en gennemgang af regnskabet med ledelsen fra RTX, som også vil svare på spørgsmål fra publikum.

Dagens aktienyheder med Hafnia, MapsPeople og ExpreS2ion